Undersecretary of health Hugo López gatell reported that Mexico’s research and higher education institutions conduct clinical trials to combat Covid-19. They have also joined global efforts to try to combat coronavirus.
He also said that they currently have 4 clinical trials and others that will be starting in the coming days.
He added that the first trial is based on the use of remdesivir, “an antiviral that has been used little” still in the world. However, it “seems promising” in some of the preliminary research to combat this disease.
The second is a controlled clinical trial of a protein called tocilizumab. A monoclonal antibody that blocks one of the mechanisms that cause inflammation of tissues, particularly lung tissue.
“Because the inflammatory effect of coronavirus on the lungs, it is the leading cause of severe acute lung damage. This medicine is considered to be promising.“
The third trial is on hydroxychloroquine, a malaria drug. It has been known for a long time and is also used for immune modulation in rheumatic diseases “and there is preliminary evidence of its potential”.
While the fourth test, it is about a substance similar to chloroquine. It is the original analogous product of hydroxychloroquine in combination with azithromycin; Lopez Gatell pointed out. A widely used antibacterial.
— COFEPRIS (@COFEPRIS) March 31, 2020
Despite all the progress the undersecretary warned that before recommending its use, it will be tested to ensure that they have no side effect or inappropriate effect on people.
Gatell explained that the Federal Commission for the Protection of Health Risks (Cofepris) has already approved three of the four clinical trials and is in the process of approving the fourth.
Mexico arrived on 1,215 Covid-19 infections and 29 deaths on Tuesday, the country’s health authorities reported.
The director general of Epidemiology of the Secretary of Health, Jose Luis Alomia, said that health authorities have other 3511 suspected cases of the disease recorded.
40 YEARS IN THE MARKET “CLOROQUINA”
A few days ago, the president of Mexico’s National Pharmacy Association, Antonio Pascual Feria, explained that chloroquine “is a product that has 40 years on the market”, while hydroxychloroquine, a derivative of chloroquine, “is a drug that has more than 60 years in the market.“
WHO (World Health Organization) has recognized that several clinical trials with Western and traditional medicines are ongoing in different countries and will provide up-to-date information as soon as results become available.